Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
46
DWTX Quote, Financials, Valuation and Earnings
Last price:
$6.00
Seasonality move
:
15.21%
Day range:
$6.00 - $6.15
52-week range:
$1.87 - $29.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.66x
Volume:
36.2K
Avg. volume:
49.9K
1-year change:
162.45%
Market cap:
$13.8M
Revenue:
--
EPS (TTM):
-$24.93
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Dogwood Therapeutics, Inc. has 205.05% upside to fair value with a price target of $18.33 per share.
DWTX vs. S&P 500
-
Over the past 5 trading days, Dogwood Therapeutics, Inc. has underperformed the S&P 500 by -8.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dogwood Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dogwood Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Dogwood Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Dogwood Therapeutics, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Dogwood Therapeutics, Inc. reported earnings per share of -$8.20.
Enterprise value:
114.3M
EV / Invested capital:
1.47x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-6.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$63.8K
Return On Assets:
-49.09%
Net Income Margin (TTM):
--
Return On Equity:
-121.03%
Return On Invested Capital:
-58.95%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -$63.8K | -- | -$17.3K | |
| Operating Income | -$6.4M | -$5.8M | -$31.7M | -$2.3M | -$15.8M | |
| EBITDA | -$6.4M | -$5.8M | -$31.6M | -$2.3M | -$15.8M | |
| Diluted EPS | -$8.43 | -$6.31 | -$24.93 | -$2.05 | -$8.20 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $20.1M | $10.9M | $5.2M | $2.3M | $11.7M | |
| Total Assets | $20.1M | $10.9M | $5.2M | $2.3M | $92M | |
| Current Liabilities | $1.2M | $1.6M | $487.1K | $1.3M | $2.6M | |
| Total Liabilities | $1.2M | $1.6M | $487.1K | $1.3M | $14.6M | |
| Total Equity | $18.9M | $9.2M | $4.8M | $949.4K | $77.4M | |
| Total Debt | -- | -- | -- | -- | $120.2K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.1M | -$4.1M | -$18.1M | -$910.1K | -$3.3M | |
| Cash From Investing | -- | -- | $3.8M | -- | -- | |
| Cash From Financing | $1.1M | $1.4M | $22.6M | -$70.2K | -- | |
| Free Cash Flow | -$6.1M | -$4.1M | -$18.1M | -$910.1K | -$3.3M | |
DWTX
Sector
Market Cap
$13.8M
$28.5M
Price % of 52-Week High
20.53%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-111.06%
-1.33%
1-Year Price Total Return
162.45%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.30
200-day SMA
Buy
Level
$5.33
Bollinger Bands (100)
Buy
Level
4.77 - 6.21
Chaikin Money Flow
Sell
Level
-58.7M
20-day SMA
Buy
Level
$6.00
Relative Strength Index (RSI14)
Sell
Level
49.06
ADX Line
Sell
Level
11.44
Williams %R
Neutral
Level
-48.6301
50-day SMA
Sell
Level
$6.10
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
263.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2434)
Sell
CA Score
(Annual)
Level (-4.083)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (5.4994)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.
Stock Forecast FAQ
In the current month, DWTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DWTX average analyst price target in the past 3 months is $18.33.
-
Where Will Dogwood Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dogwood Therapeutics, Inc. share price will rise to $18.33 per share over the next 12 months.
-
What Do Analysts Say About Dogwood Therapeutics, Inc.?
Analysts are divided on their view about Dogwood Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dogwood Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Dogwood Therapeutics, Inc.'s Price Target?
The price target for Dogwood Therapeutics, Inc. over the next 1-year time period is forecast to be $18.33 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DWTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dogwood Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of DWTX?
You can purchase shares of Dogwood Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dogwood Therapeutics, Inc. shares.
-
What Is The Dogwood Therapeutics, Inc. Share Price Today?
Dogwood Therapeutics, Inc. was last trading at $6.00 per share. This represents the most recent stock quote for Dogwood Therapeutics, Inc.. Yesterday, Dogwood Therapeutics, Inc. closed at $6.01 per share.
-
How To Buy Dogwood Therapeutics, Inc. Stock Online?
In order to purchase Dogwood Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get DWTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DWTX
Sector
P/E ratio
--
23.75x
PEG ratio
0.00x
-0.01x
P/B ratio
0.66x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
DWTX
Sector
Revenue growth
--
4.85%
Earnings growth
-299.35%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.20
Profitability
DWTX
Sector
Profitability FY 2024
-$12.2K
$3.6M
Return on invested capital
-58.95%
-30.98%
Return on assets
-49.09%
-27.62%
Return on equity
-121.03%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
5
Balance Sheet
DWTX
Sector
Total cash
$10.1M
$27.2M
Short term investments
--
$25.7M
Total assets
$101.2M
$79.7M
Long term debt
$120.2K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 66.31% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.14% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.55% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
